Detailed answers about PHARMA ENGINEERING COMPLIANCE SOLUTIONS LTD., including incorporation, status, business activity, and accounts information.
When was PHARMA ENGINEERING COMPLIANCE SOLUTIONS LTD. founded?
PHARMA ENGINEERING COMPLIANCE SOLUTIONS LTD. was officially incorporated on 13 July 2015 and is registered under company number 09682178. Incorporation establishes the company as a legal entity registered at Companies House, allowing it to trade, enter contracts, and operate under UK company law.
What type of company is PHARMA ENGINEERING COMPLIANCE SOLUTIONS LTD.?
Private Limited Company. This classification indicates the legal structure of the company, which determines the way it is governed, its liability, and regulatory obligations. A private limited company (Ltd) limits the personal liability of its shareholders.
What is the current status of PHARMA ENGINEERING COMPLIANCE SOLUTIONS LTD.?
PHARMA ENGINEERING COMPLIANCE SOLUTIONS LTD.'s current status is Active. The company status indicates whether it is actively trading, dormant, or has been dissolved. Maintaining an active status is essential for legally conducting business, filing accounts, and maintaining credibility with partners and lenders.
What does PHARMA ENGINEERING COMPLIANCE SOLUTIONS LTD. do?
PHARMA ENGINEERING COMPLIANCE SOLUTIONS LTD. operates in the following sector: 70229 - Management consultancy activities other than financial management. This provides insight into the company's primary business activity and industry focus.
What is PHARMA ENGINEERING COMPLIANCE SOLUTIONS LTD.'s registered address?
The registered office address of PHARMA ENGINEERING COMPLIANCE SOLUTIONS LTD. is 15 LANVILLE ROAD, LIVERPOOL, UNITED KINGDOM, L19 7NJ. This is the official address filed with Companies House for legal and statutory correspondence.
Is PHARMA ENGINEERING COMPLIANCE SOLUTIONS LTD. financially stable?
The most recent accounts for PHARMA ENGINEERING COMPLIANCE SOLUTIONS LTD. were made up to 31 July 2024, filed as TOTAL EXEMPTION FULL. Next accounts are due by 30 April 2026.